Sodium-glucose cotransporter-2 inhibitors (SGLT2i) had been established in type 2 diabetes (T2D) care for some time when their positive impact on cardiovascular (CV) outcomes—including heart failure (HF)—was recognized [1–4]. The gene discussed is SLC5A2; the disease is hydrops fetalis.